Clinical Trial Update: Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating camrelizumab in combination with irinotecan or albumin-bound paclitaxel for second-line advanced gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Albumin-bound paclitaxel (nab-paclitaxel)
• Camrelizumab (camrelizumab)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Second Line Treatment of Gastric Cancer | Phase 2 | Status: UNKNOWN